Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins

This phase 2 trial tests whether daraxonrasib, an oral drug that targets cancers with a KRAS mutation, can shrink tumors in people with advanced biliary tract cancer that has progressed after first-line treatment. Participants take the drug once daily in 28-day cycles. The main g…

This trial is testing whether two oral drugs, avutometinib and defactinib, can be safely given to people with newly diagnosed high-grade gliomas, a type of aggressive brain cancer. Participants first take the drugs for one cycle before starting standard radiation, and those with …

This early-stage trial tests a new vaccine that targets a specific protein found only in fibrolamellar liver cancer cells. The vaccine is combined with three other drugs to boost the immune system and block cancer growth. About 27 people with advanced disease who have already tri…

This study tests whether adding a radioactive drug called 177Lu-PSMA-617 to standard radiation therapy can allow men with high-risk localized prostate cancer to take hormone therapy for only 6 months instead of the usual 24 months. The goal is to see if this approach is as effect…

This phase 2 trial is testing whether adding an experimental drug called DCSZ11 to standard radiation and chemotherapy can improve outcomes for people with a high-risk type of rectal cancer. The study will enroll 30 adults who have not had prior treatment. The goal is to see if t…

Researchers at Johns Hopkins are testing whether a blood test called Signatera can reliably detect tumor DNA in people with high-grade upper tract urothelial cancer, a rare cancer of the urinary tract. The study will collect blood samples before, during, and after treatment to se…